Drug Safety

, Volume 24, Issue 3, pp 167–182 | Cite as

Interaction between Aspirin and ACE Inhibitors in Patients with Heart Failure

  • Isabelle Mahé
  • Christophe Meune
  • Myriam Diemer
  • Charles Caulin
  • Jean-François Bergmann
Review Article

Abstract

Both aspirin (acetylsalicylic acid) and ACE inhibitors are often used concomitantly, especially in patients with both heart failure and ischaemic heart disease, which is the most common underlying cause of heart failure.

The safety of the association has been questioned because both drugs affect a related prostaglandin-mediated pathway. Thanks to their vasodilating properties, prostaglandins play an important role in heart failure where peripheral vasoconstriction occurs. Some of the beneficial effects of ACE inhibitors might be related to reduced degradation of bradykinin that enhances the synthesis of prostaglandins, while aspirin, through inhibiting the enzyme cyclo-oxygenase, inhibits the production of prostaglandins.

To date no prospective study has been conducted to investigate the effect of long term aspirin treatment in the postinfarction period allowing the possible impact of the interaction between aspirin and ACE inhibitors upon survival to be confirmed or negated. However, the practitioner needs to know how to optimise the treatment of his or her patients.

In order to stimulate arguments for and against the use of aspirin in patients with heart failure receiving ACE inhibitors, we searched MEDLINE from 1960 to 2000 using the key words heart failure, aspirin, and ACE inhibitors for English language articles and conducted a review of the available data.

We report on the potential mechanisms of the interaction and the results of experimental studies on haemodynamic parameters. Results of retrospective clinical studies, subgroup analysis that were undertaken to evaluate the overall action upon haemodynamic parameters and survival of the association are summarised. Conflicting conclusions have been reported in the literature. Many explanations can be advanced to try to understand these conflicting conclusions: differences in study design (results of retrospective trials have to be interpreted with caution); differences in the choice of the evaluation parameter (problem of the clinical relevance of haemodynamic parameters); differences in the characteristics of the patient (different underlying cardiopathy, e.g. heart failure, hypertension or ischaemic cardiopathy); and differences in the type and the dosage of each treatment (especially ACE inhibitors and aspirin since an interaction might occur more often with dosage of aspirin greater than 250mg).

References

  1. 1.
    Goldberg RJ. Assessing the population burden from heart failure. Arch Intern Med 1999; 159: 15–7PubMedCrossRefGoogle Scholar
  2. 2.
    Cowie MR, Mosterd A, Wood DA, et al. The epidemiology of heart failure. Eur Heart J 1997 18: 208–25PubMedCrossRefGoogle Scholar
  3. 3.
    Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J 1997; 133: 703–12PubMedCrossRefGoogle Scholar
  4. 4.
    Teerlink JR, Goldhaber SZ, Pfeffer MA. An overview of contemporary etiologies of congestive heart failure. Am Heart J 1991; 121: 1852–3PubMedCrossRefGoogle Scholar
  5. 5.
    Ho KKL, Pinsky JL, Kannel WB, et al. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993; 22SupplA: 6A–13APubMedCrossRefGoogle Scholar
  6. 6.
    Cleland JGF, Bulpitt CJ, Falk RH, et al. Is aspirin safe for patients with heart failure? Br Heart J 1995; 74: 215–9PubMedCrossRefGoogle Scholar
  7. 7.
    Leor J, Reicher-Reiss H, Goldbourt U, et al. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors. A cohort of 11575 patients with coronary heart disease. J Am Coll Cardiol 1999; 33: 1920–5PubMedCrossRefGoogle Scholar
  8. 8.
    Garcia-Dorado D, Velasco Rami J, Virgos Lamela A, et al. Interaction between antiplatelets agents and ACE inhibitors in patients with acute myocardial infarction. Eur Heart J 1999; 1SupplF: 24F–28FGoogle Scholar
  9. 9.
    Nawarskas JJ, Spinler SA. Does aspirin interfere with the therapeutic efficacy of angiotensin-converting enzyme inhibitors in hypertension or congestive heart failure? Pharmacotherapy 1998; 18: 1041–52PubMedGoogle Scholar
  10. 10.
    Teerlink JR, Massie BM. The interaction of ACE inhibitors and aspirin in heart failure: torn between two lovers. Am Heart J 1999; 138: 193–7PubMedCrossRefGoogle Scholar
  11. 11.
    Song KH, Fedyk R, Hoover R. Interaction of ACE inhibitors and aspirin in patients with congestive heart failure. Ann Pharmacother 1999; 33: 375–7PubMedCrossRefGoogle Scholar
  12. 12.
    Stys T, Lawson WE, Smaldone GC, et al. Does aspirin attenuate the beneficial effects of angiotensin-converting enzyme inhibition in heart failure? Arch Med Intern 2000 160: 1409–13CrossRefGoogle Scholar
  13. 13.
    The SOLVD Investigators. Effects of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991; 325: 293–302Google Scholar
  14. 14.
    Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991 325: 303–10PubMedCrossRefGoogle Scholar
  15. 15.
    CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429–35Google Scholar
  16. 16.
    Latini R, Maggioni AP, Flather M, et al. ACE inhibitors use in patients with myocardial infarction: summary of evidence from clinical trials. Circulation 1995 92: 3132–7PubMedCrossRefGoogle Scholar
  17. 17.
    Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669–77PubMedCrossRefGoogle Scholar
  18. 18.
    The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–8Google Scholar
  19. 19.
    Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995 333: 1670–6PubMedCrossRefGoogle Scholar
  20. 20.
    Garg R, Yusus S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450–6PubMedCrossRefGoogle Scholar
  21. 21.
    The Task Force of the Working Group on Heart Failure of the European Society of Cardiology. The treatment of heart failure. Eur Heart J 1997; 18: 736–53Google Scholar
  22. 22.
    ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction. Circulation 1998; 97: 2202–12Google Scholar
  23. 23.
    Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation 1997; 96: 2751–3PubMedCrossRefGoogle Scholar
  24. 24.
    ISIS-2 (Second International Study of Infarct Survival) collaborative group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; II: 349–60Google Scholar
  25. 25.
    Baigent C, Collins R, Appleby P, et al. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) collaborative group. BMJ 1998; 316: 1337–43PubMedCrossRefGoogle Scholar
  26. 26.
    Antiplatelet Trialists Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988; 296: 320–31Google Scholar
  27. 27.
    Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106Google Scholar
  28. 28.
    Aspirin Myocardal Infarction Study Research Group. A randomised, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 1980; 243: 661–8Google Scholar
  29. 29.
    The Persantine-Aspirin Reinfarction Study (PARIS) Research Group. Persantine and aspirin in coronary disease. Circulation 1980; 62: 449–62Google Scholar
  30. 30.
    Hennekens CH, Albert CM, Godfried SL, et al. Adjunctive drug therapy of acute myocardial infarction: evidence from clinical trials. N Engl J Med 1996 335: 1660–7PubMedCrossRefGoogle Scholar
  31. 31.
    Patten RD, Udelson JE, Konstam MA. Ventricular remodeling and its prevention in the treatment of heart failure. Curr Opin Cardiol 1998; 13: 162–7PubMedGoogle Scholar
  32. 32.
    Bönner G. The role of kinins in the antihypertensive and cardioprotective effects of ACE inhibitors. Drugs 1997; 54Suppl. 5: 23–30PubMedCrossRefGoogle Scholar
  33. 33.
    Williams GH, Dluhy RG. Control of aldosterone secretion. In: Genest J, Kuchel O, Hamet P, et al., editors. Hypertension: physiopathology and treatment, 2nd ed. New York (NY): McGraw-Hill, 1983: 320–38Google Scholar
  34. 34.
    Schwieler JH, Kahan T, Nussberger J, et al. Converting enzyme inhibition modulates sympathetic neurotransmission in vivo via multiple mechanisms. Am J Physiol 1993 264: E631–7PubMedGoogle Scholar
  35. 35.
    Mason DT, Melmon KL. Effects of bradykinin on forearm venous tone and vascular resistance in man. Circ Res 1965; 17: 106–13PubMedCrossRefGoogle Scholar
  36. 36.
    Schrör K. Role of prostaglandins in the cardiovascular effects of bradykinin and angiotensin-converting inhibitors. J Cardiovasc Pharmacol 1992; 20Suppl. S: 68S–73SCrossRefGoogle Scholar
  37. 37.
    Cockroft JR, Chowienczyk PJ, Chrosch R, et al. Inhibition of bradykinin-induced vasodilation in the human forearm vasculature by iactibant, a B2-receptor antagonist. Br J Clin Pharmacol 1994 38: 317–22CrossRefGoogle Scholar
  38. 38.
    Dzau VJ, Packer M, Lilly LS, et al. Prostaglandins in severe congestive heart failure. Relation to activation of the renin-angiotensin system and hyponatremia. N Engl J Med 1984 310: 347–52PubMedCrossRefGoogle Scholar
  39. 39.
    Böger RH, Bode-Böger SM, Kramme P, et al. Effect of captopril on prostacyclin and nitric oxide formation in healthy human subjects: interaction with low dose acetylsalicylic acid. Br J Pharmacol 1996; 42: 721–7Google Scholar
  40. 40.
    Gottlieb SS, Robinson S, Krichten CM, et al. Renal response to indomethacin in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1992 70: 890–3PubMedCrossRefGoogle Scholar
  41. 41.
    Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997; 95: 1115–8PubMedCrossRefGoogle Scholar
  42. 42.
    Luque M, Martin P, Martell N, et al. Effects of captopril related to increased levels of prostacyclin and angiotensin (1-7) in essential hypertension. J Hypertens 1996 14: 799–805PubMedCrossRefGoogle Scholar
  43. 43.
    Davie AP, Dargie HJ, McMurray JJV. Role of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure. Circulation 1999; 100: 268–73PubMedCrossRefGoogle Scholar
  44. 44.
    Dzeka TN, Kuzminski P, Arnold JMO. Venous responsiveness to norepinephrine in healthy subjects: effects of single doses of 325mg aspirin. Clin Pharmacol Ther 2000; 67: 299–304PubMedCrossRefGoogle Scholar
  45. 45.
    Smith SR, Coffman TM, Svetkey LP. Effect of low-dose aspirin on thromboxane production and the antihypertensive effect of captopril. J Am Soc Nephrol 1993; 4: 1133–9PubMedGoogle Scholar
  46. 46.
    Baur LH, Schipperheyn JJ, van der Laarse A, et al. Combining salicylate and enalapril in patients with coronary artery disease and heart failure. Br Heart J 1995; 73: 227–36PubMedCrossRefGoogle Scholar
  47. 47.
    Van Wijngaarden J, Smit AJ, de Graeff PA, et al. Effects of acetylsalicylic acid on peripheral hemodynamics in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 1994 23: 240–5PubMedCrossRefGoogle Scholar
  48. 48.
    Tweeddale MG, Ogilvie RI. Antagonism of spironolactone-induced natriuresis by aspirin in man. N Engl J Med 1973; 289: 198–200PubMedCrossRefGoogle Scholar
  49. 49.
    Haynes G, Webb DJ. Endothelium-dependent modulation of responses to endothelin-1 in human veins. Clin Sci 1993; 84: 427–33PubMedGoogle Scholar
  50. 50.
    Quilley J, Duchin KL, Hudes EM, et al. The antihypertensive effect of captopril in hypertension: relationship to prostaglandins and the kallikrein-kinin system. J Hypertens 1987; 5: 121–8PubMedCrossRefGoogle Scholar
  51. 51.
    Moroi M, Akatsuka N, Fukazawa M, et al. Endothelium-dependent relaxation by angiotensin-converting enzyme inhibitors in canine femoral arteries. Am J Physiol 1994 266: 583–9Google Scholar
  52. 52.
    Evans MA, Burnett Jr CJ, Redfield MM. Effect of low dose aspirin on cardiorenal function and acute hemodynamic response to enalaprilat in a canine model of severe heart failure. J Am Coll Cardiol 1995; 25: 1445–50PubMedCrossRefGoogle Scholar
  53. 53.
    Stauss HM, Zhu YC, Redlich T, et al. Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II. J Cardiovasc Risk 1994 1: 255–62PubMedGoogle Scholar
  54. 54.
    Rose J, Ehring T, Sakka SG, et al. Aspirin does not prevent the attenuation of myocardial stunning by the ACE inhibitor ramiprilat. J Mol Cell Cardiol 1996 28: 608–13CrossRefGoogle Scholar
  55. 55.
    Nishimura H, Kubo S, Ueyama M, et al. Peripheral hemodynamic effects of captopril in patients with congestive heart failure. Am Heart J 1989 117: 100–5PubMedCrossRefGoogle Scholar
  56. 56.
    Nakamura M, Funakoshi T, Arakawa N, et al. Effect of angiotensin-converting enzyme inhibitors on endothelium-dependent peripheral vasodilation in patients with chronic heart failure. J Am Coll Cardiol 1994 24: 1321–7PubMedCrossRefGoogle Scholar
  57. 57.
    Katz SD, Radin M, Graves T, et al. Effect of aspirin and ifetroban on skeletal muscle blood flow in patients with congestive heart failure treated with enalapril. J Am Coll Cardiol 1999 34: 170–6PubMedCrossRefGoogle Scholar
  58. 58.
    Jeserich M, Pape L, Just H, et al. Effect of long-term angiotensin-converting enzyme inhibition on vascular function in patients with chronic congestive heart failure. Am J Cardiol 1995 76: 1079–82PubMedCrossRefGoogle Scholar
  59. 59.
    Hall D, Zeitler H, Rudolf W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 1992; 20: 1549–55PubMedCrossRefGoogle Scholar
  60. 60.
    Townend JN, Doran J, Lote CJ, et al. Peripheral haemodynamic effects on inhibition of prostaglandin synthesis in congestive heart failure and interactions with captopril. Br Heart J 1995 73: 434–41PubMedCrossRefGoogle Scholar
  61. 61.
    Spaulding C, Charbonnier B, Cohen-Solal A, et al. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: results of a double blind randomized comparative trial. Circulation 1998 98: 757–65PubMedCrossRefGoogle Scholar
  62. 62.
    Riegger GA, Kahles HW, Elsner D, et al. Effects of acetylsalicylic acid on renal function in patients with chronic heart failure. Am J Med 1991 90: 571–5PubMedGoogle Scholar
  63. 63.
    Dietz R, Nagel F, Osterziel K. Angiotensin-converting enzyme inhibitors and renal function in heart failure. Am J Cardiol 1992; 70Suppl. C: 119C–25CPubMedCrossRefGoogle Scholar
  64. 64.
    Schwartz D, Kornowski R, Lehman H, et al. Combined effect of captopril and aspirin on renal haemodynamics in elderly patients with congestive heart failure. Cardiology 1992 81: 334–9PubMedCrossRefGoogle Scholar
  65. 65.
    Guazzi M, Pontone G, Agostini P, et al. Aspirin worsens exercise performance and pulmonary gas exchange in patients with heart failure who are taking angiotensin-converting enzyme inhibitors. Am Heart J 1999 138: 254–60PubMedCrossRefGoogle Scholar
  66. 66.
    Guazzi M, Marenzi G, Alimento M, et al. Improvement of alveolar-capillary membrane diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin. Circulation 1997 95: 1930–6PubMedCrossRefGoogle Scholar
  67. 67.
    Guazzi M, Melzi G, Agostini P. Comparison of changes in respiratory function and exercise oxygen uptake with losartan versus enalapril in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1997; 80: 1572–6PubMedCrossRefGoogle Scholar
  68. 68.
    Guazzi M, Agostini P. Decrease by ACE-inhibition of the excessive alveolar-capillary membrane resistance to gas transfer in chronic heart failure. Cardiologia 1998; 43: 625–30PubMedGoogle Scholar
  69. 69.
    Dickstein K, Barvik S, Aarsland T. Effect of long-term enalapril therapy on cardiopulmonary exercise performance in men with mild heart failure and previous myocardial infarction. J Am Coll Cardiol 1991; 18: 596–602PubMedCrossRefGoogle Scholar
  70. 70.
    Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992 340: 1173–8PubMedCrossRefGoogle Scholar
  71. 71.
    Cleland JGF. Anticoagulation and antiplatelet therapy in heart failure. Curr Opinion Cardiol 1997; 12: 276–87CrossRefGoogle Scholar
  72. 72.
    Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000 355: 1575–81PubMedCrossRefGoogle Scholar
  73. 73.
    Latini R, Tognoni G, Maggioni AP, et al. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96712 randomised patients. J Am Coll Cardiol 2000; 3(7): 1801–7CrossRefGoogle Scholar
  74. 74.
    Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol 1997; 79: 115–9PubMedCrossRefGoogle Scholar
  75. 75.
    Zuanetti G, Latini R, Maggioni AP, et al. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction. Data from the GISSI-3. Circulation 1997 96: 4239–45PubMedCrossRefGoogle Scholar
  76. 76.
    Goldbourt U, Behar S, Reicher-Reiss H, et al. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol 1993 71: 909–15PubMedCrossRefGoogle Scholar
  77. 77.
    Coats AJS. Enalapril, aspirin interaction. Am J Cardiol 1997; 80(8): 1122PubMedGoogle Scholar
  78. 78.
    Al-Khadra AS, Salem DN, Rand WM, et al. Antiplatelets agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Trial. J Am Coll Cardiol 1998 31: 419–25PubMedCrossRefGoogle Scholar
  79. 79.
    Oosterga M, Anthonio RL, deKam PJ, et al. Effects of aspirin on angiotensin-converting enzyme inhibition and left ventricular dilatation one year after acute myocardial infarction. Am J Cardiol 1998 81: 1178–81PubMedCrossRefGoogle Scholar
  80. 80.
    Davie AP. Effects of aspirin on angiotensin-converting enzyme inhibition and left ventricular dilation one year after acute myocardial infarction. Am J Cardiol 1999; 83: 641PubMedCrossRefGoogle Scholar
  81. 81.
    Aumégeat V, de Groote P, Meurice T, et al. Aspirin and angiotensin-converting enzyme inhibitors in 445 patients with moderate congestive heart failure [abstract]. J Am Coll Cardiol 1999 33: 214AGoogle Scholar
  82. 82.
    Guazzi M, Campodonico J, Celeste F. Antihypertensive efficacy of angiotensin converting enzyme inhibition and aspirin counteraction. Clin Pharmacother 1998; 63: 79–86Google Scholar
  83. 83.
    Polonia J, Boaventura I, Gama G, et al. Influence of non-steroidal anti-inflammatory drugs on renal function and 24h ambulatory blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients. J Hypertens 1995 13: 925–31PubMedCrossRefGoogle Scholar
  84. 84.
    Nawarskas JJ, Townsend RR, Cirigliano MD, et al. Effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan. Am J Hypertens 1999 12: 784–9PubMedCrossRefGoogle Scholar
  85. 85.
    Peterson JG, Laur MS, Young JB, et al. Evidence for an adverse interaction between ACE inhibitors and aspirin following myocardial infarction: the GUSTO-I Trial [abstract]. J Am Coll Cardiol 1998; 31Suppl A: 96ACrossRefGoogle Scholar
  86. 86.
    The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–53Google Scholar
  87. 87.
    Hornig B, Arakawa N, Drexler H. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with heart failure. Circulation 1998; 98: 2842–8PubMedCrossRefGoogle Scholar
  88. 88.
    Davie AP, Love MP, McMurray JJ. Even low-dose aspirin inhibits arachidonic acid-induced vasodilation in heart failure. Clin Pharmacol Ther 2000; 67: 530–7PubMedCrossRefGoogle Scholar
  89. 89.
    The WASH Study Steering Committee and Investigators. The WASH Study/Warfarin/Aspirin Study in Heart Failure: rationale design and end points. Eur J Heart Failure 1999; 1: 95–9Google Scholar
  90. 90.
    Cokkinos DV, Toutouzas PK. Antithrombotic therapy in heart failure: a randomised comparison of warfarin vs aspirin (HELAS). Eur J Heart Failure 1999; 1: 419–23CrossRefGoogle Scholar
  91. 91.
    Pfeffer MA. ACE Inhibitor in acute myocardial infarction. Patient selection and timing. Circulation 1998; 97: 2192–4PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  • Isabelle Mahé
    • 1
  • Christophe Meune
    • 1
  • Myriam Diemer
    • 1
  • Charles Caulin
    • 1
  • Jean-François Bergmann
    • 1
  1. 1.Unité de Recherches Thérapeutiques, Service de Médicine Interne AHôpital LariboisièreParisFrance

Personalised recommendations